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ABSTRACT
Introduction: Women with metabolic risk factors are
at higher risk of adverse pregnancy outcomes.
Mediterranean-based dietary interventions have the
potential to minimise these risks. We aim to evaluate
the effectiveness of a simple, targeted intervention
modelled on Mediterranean diet in preventing maternal
and fetal complications in pregnant women with
metabolic risk factors.
Methods and analysis: Pregnant women with a
singleton pregnancy <18 weeks gestation, and without
pre-existing diabetes, chronic renal disease and
autoimmune diseases will be recruited. Women with
metabolic risk factors will be randomised to receive a
dietary intervention based on a Mediterranean pattern,
supplemented with extra virgin olive oil and mixed nuts
until delivery. The intervention will be delivered through
a series of one to one and group sessions. The primary
outcome is a composite maternal outcome of pre-
eclampsia or gestational diabetes and a composite fetal
outcome of stillbirth, small for gestational age fetus or
admission to the neonatal intensive care unit. Secondary
outcomes include maternal, fetal, dietary and laboratory
outcomes. We aim to randomise 1230 eligible women
with metabolic risk factors. We will also compare the
outcomes in women with and without these risk factors.
The sample size will provide us with 80% power at 5%
significance, assuming a 20% loss to follow-up to detect
a 30% reduction in maternal and fetal complications.
Ethics and dissemination: The ESTEEM trial is
designed to provide a definitive estimate of the effects
of Mediterranean dietary pattern in pregnancy on
maternal and fetal outcomes. The pragmatic nature of
ESTEEM ensures the applicability of its findings into
clinical practice. The findings of the study will be
published in peer-reviewed journals and presented at
national and international scientific meetings and
congresses. Ethical approval was granted by the NHS
Research Ethics Committees (14/EE/1048).
Trial registration number: NCT02218931;
Pre-results.
INTRODUCTION
Obesity is rapidly increasing worldwide
adversely affecting public health.1 Pregnant
women with metabolic risk factors such as
increased adiposity and dyslipidaemia are at
high risk of adverse pregnancy outcomes.2
About one in ﬁve women currently enter
pregnancy as obese in the UK, leading to
complications such as gestational diabetes,
pre-eclampsia, stillbirth and neonatal death.3
High levels of triglycerides and cholesterol
are independent risk factors for pre-
eclampsia and diabetes in pregnancy.4 5 Poor
dietary habits, sedentary lifestyle and under-
lying genetic predisposition all contribute to
this phenomenon. Diet and physical activity
based interventions have shown a beneﬁcial
effect on gestational weight gain, with varied
effect on pregnancy outcomes.6
The Mediterranean dietary pattern has
demonstrated a beneﬁcial effect in reducing
metabolic risk factors such as adiposity,
hypertension and dyslipidemia.7 In non-
pregnant individuals with metabolic risk
factors, a Mediterranean diet-based interven-
tion supplemented with extra virgin olive oil
Strengths and limitations of this study
▪ Large sample size to provide adequate power to
detect a reduction in composite maternal and
fetal outcomes.
▪ Pragmatic design to facilitate the translation of
findings into clinical practice.
▪ Advocating healthy lifestyle changes.
▪ Objective assessment of adherence.
▪ Unblinded intervention.
▪ Variations in care provision for the control group.
Al Wattar BH, et al. BMJ Open 2016;6:e013495. doi:10.1136/bmjopen-2016-013495 1
Open Access Protocol
group.bmj.com on October 26, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
and nuts was shown to reduce cardiovascular mortality
and morbidity.8 Observational studies in pregnancy have
reported a reduction in the risk of pre-eclampsia, gesta-
tional diabetes and fetal growth restriction in women
with high compliance to a Mediterranean-based diet
compared to those with low compliance.9–11 However,
the existing studies in this population are non-
randomised, of poor quality, or focus on speciﬁc compo-
nents of the diet, rather than modifying the overall
dietary pattern.6
There is a need for an adequately powered pragmatic
randomised trial to evaluate the beneﬁcial effect of a
Mediterranean diet in pregnancy that is simple, feasible
and targeting women at most risk of complications.
OBJECTIVES
We aim to assess the effects of Mediterranean diet-based
intervention in high-risk pregnant women to minimise
maternal and fetal complications.
Our primary objective is to compare, in pregnant
women with metabolic risk factors, the effect of a
simple, targeted Mediterranean-based diet, supplemen-
ted with extra virgin olive oil and nuts, composed within
culturally appropriate recipes and food options, on a
composite maternal (pre-eclampsia or gestational dia-
betes) and fetal outcome (stillbirth, small for gestational
age fetus or admission to neonatal intensive care unit),
to current care.
The secondary objectives are to assess the effect of the
dietary intervention on different individual maternal
and fetal complications and on the participants’ lipid
proﬁle in the two randomised groups. We will also evalu-
ate the risk of complications in women with and without
metabolic risk factors in the recruited cohort.
Furthermore, we will study the effect of the dietary inter-
vention on the risk of composite maternal and fetal out-
comes in the following subgroups: obese women,
women with raised triglycerides and women with
chronic hypertension.
METHODS AND ANALYSIS
Study design
ESTEEM is a parallel group randomised trial embedded
in a cohort study.
Setting
Secondary and tertiary care maternity units in England
from September 2014 to September 2016.
Participants
Eligibility for recruitment
Women are eligible to participate in the ESTEEM study
if they are pregnant with singleton fetus of <18 weeks
gestation, are 16 years old or more, have a body mass
index (BMI) between 18.5 and 40 kg/m2, are able to
consume nuts and olive oil, follow a Mediterranean
dietary pattern and have a good understanding of
written and spoken English. Participants are excluded if
they have a history of pre-existing diabetes, chronic renal
disease and autoimmune disease or if they are on any
lipid-altering drugs, for example, statins
Eligibility for randomisation
Women will be randomised to the trial if they have any
of the following risk factors: obesity (BMI ≥30 kg/m2),
raised serum triglycerides (≥1.7 mmol/L) or chronic
hypertension (≥140 mm Hg systolic or ≥90 mm Hg dia-
stolic blood pressure).
Study conduct
Pregnant women will be provided with the ESTEEM
Patient Information Sheet (PIS) at least 24 hours prior
to the hospital booking visit to ensure that they have
adequate time to consider the trial. If a participant has
not read or received the PIS beforehand, the research
team will explain the PIS in person. If the participant
fully understands the study and is keen to join, a written
consent form will be obtained. An additional written
consent form will be completed prospectively to collect
and store umbilical cord blood samples for use in future
studies investigating the link between the maternal diet
and the cord blood nutrients. Participants can still join
the study if they decline the cord blood collection.
Examples of both consent forms are submitted as sup-
porting information (see online supplementary
appendix 1).
Following consent, baseline information will be
obtained from the participants, blood pressure will be
measured, and an additional lipid proﬁle test will be
carried out to assess the participant’s suitability for
randomisation.
Women who fulﬁl the criteria for randomisation will
be randomly allocated to the intervention group (Group
A) or the control group (Group B). The randomisation
and sequence allocation will be performed by the trial
research staff via a password-protected internet-based
data management system in a ratio of (1:1).
Minimisation (with a random element to ensure alloca-
tion concealment) will be used to ensure balanced
groups for maternal weight, gravidity and ethnicity.
Women with no metabolic risk factors will be followed
up as a non-randomised cohort and maternal and fetal
outcomes will be obtained (Group C) (ﬁgure 1).
Women randomised to the intervention will be invited
to the ESTEEM antenatal clinic to meet the study diet-
ician or a trained allied health professional before
18 weeks, who will deliver the dietary intervention on a
1-1 basis. Women will be invited to two further sessions
at 20 and 28 weeks gestation for delivery of the interven-
tion in a group setting. Two follow-up phone calls will be
made to the participants in the intervention group at 24
and 32 weeks gestation to check on their well-being,
assess their compliance using the ESTEEM question-
naire and check for any adverse events (AEs).
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Participants in the intervention group who miss the
ﬁrst appointment in which intervention is delivered will
be given another appointment at 20 weeks of gestation.
Any participant who fails to attend subsequent group
sessions will be kept in the intervention group, if they
continue to collect the nuts and olive oil and adhere to
the intervention. Group sessions and telephone follow-
ups will have a 2-week window for completion of tasks.
Failure to complete the follow-up in time will be
recorded as a deviation of protocol, and records will be
updated accordingly.
Baseline information, as well as ESTEEM Q, IPAQ and
EQ5D questionnaires, will be completed in person, over
the telephone or posted to all participants in the inter-
vention and the control groups. A ﬁnal 1-1 follow-up
session will be offered between 36 weeks gestation and
delivery to women in both groups. The aim of this
session is to assess dietary intake, physical activity, quality
of life, repeat the serum lipids proﬁle blood test and
measure their weight and blood pressure (ﬁgure 2).
Health technology assessed
The ESTEEM dietary intervention is based on
Mediterranean diet, with education to modify lifestyle
choices. The key components of the diet include high
intake of fruit and vegetables, non-reﬁned grains,
legumes, moderate to high consumption of ﬁsh, small to
moderate intake of poultry and dairy products such as
yoghurt and cheese, low consumption of red meat and
processed meat and avoidance of sugary drinks, fast
food and food rich in animal fat. In particular, ESTEEM
advocates high intake of nuts (including walnuts, hazel-
nuts and almonds estimated at 30 g/day) and high
intake of extra virgin olive oil as the main source of fat
(estimated at 0.5 L/week). The intervention will include
dietary education sessions, grocery shopping advice,
cooking recipes for a healthy diet and advice for appro-
priate meal choices at restaurants.
At the ﬁrst visit, the dietician or a trained allied health
professional will assess the participant’s dietary habits
using 24 hours food recall followed by focused questions
to estimate their basal dietary intake and identify ele-
ments for change towards a Mediterranean diet.
Participants will be encouraged to set and record perso-
nalised goals following the SMART model (speciﬁc,
measurable, achievable, relevant and time-speciﬁc) to
implement the highlighted changes to their diet.12
Women will also be asked to complete the ESTEEM
questionnaire (a 12 items short dietary questionnaire
speciﬁcally designed to assess the intake of
Mediterranean food groups) to provide a baseline
record. The participants’ physical activity will be assessed
using the IPAQ questionnaire,13 and their quality of life
will be assessed using the EQ-5D questionnaire.14 The
dietician or a trained allied health professional will also
provide standardised education material on the beneﬁts
Figure 1 ESTEEM study design including the screening, recruitment and randomisation process.
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of Mediterranean diet in pregnancy and supportive fact
sheets on the beneﬁts of nuts and extra virgin olive oil.
In the group sessions, mothers will be encouraged to
involve their partners and the whole family in the
dietary changes. Culturally adaptable recipes and
grocery list for foods will be provided to promote intake
of a Mediterranean lifestyle diet. Women will be advised
to modify their current diet with a healthier option
where possible, such as reducing the saturated fat and
added sugar intake. Adherence to the intervention will
be assessed primarily against the number of sessions
attended, and if needed supplemented with dietary
information collected using the ESTEEM Questionnaire
at 20, 24, 28, 32 and 36 weeks gestation.
The control group will be provided with the usual
antenatal dietary advice as per NICE guidelines on ante-
natal care, weight management in pregnancy and
hypertension in pregnancy.15–17 Folic acid and vitamin D
supplementation will be provided as per national recom-
mendations for all participants.
Umbilical cord blood samples collection and storage
Umbilical cord blood samples will be collected from all
consented participants on delivery of the baby for use in
future studies. Blood will be collected from the umbilical
cord and the placenta using a syringe and a needle and
saved in a 10 mL ethylenediaminetetraacetic acid
(EDTA) dry tubes. All samples will be stored at an accre-
dited Human Tissue Resource Centre (Barts and the
London NHS Trust) and will be stored for a maximum
of 72 hours at the site of collection. Samples will be then
transferred to an accredited tissue bank facility (The
Blizard Institute—Queen Mary University of London) to
be stored in a −80°C freezer. All samples will be coded
Figure 2 Flow chart of the ESTEEM study conduct.
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anonymously with no information identifying the study
participants. Samples will be stored in accordance with
the institutional Data Protection Policy for the lifetime
of the study and 10 years after its completion.
Proposed outcome measures
The primary outcome is a composite maternal outcome
deﬁned as pre-eclampsia (new onset or superimposed)
or gestational diabetes; and a fetal composite outcome
deﬁned as stillbirth, small for gestational age fetus (birth
weight less than 10th centile) or admission to the neo-
natal intensive care unit. The deﬁnitions are provided in
online supplementary appendix.2
The secondary outcomes are as follows: maternal: pre-
eclampsia, gestational diabetes, preterm delivery, gesta-
tional weight gain, antepartum haemorrhage, mode of
delivery, anaemia and admission to high dependency
unit or intensive care unit; fetal and neonatal: stillbirths,
neonatal deaths, hypoxic ischaemic encephalopathy,
birth weight (in kg using customised and population
centiles) small for gestational age (<10th centile) and
admission to neonatal intensive care units; dietary: nutri-
ents and food intakes, food groups, including olive oil,
vegetables, fruits, red meat, butter/margarine, sugary
drinks, pulses, ﬁsh intake and commercial sweets; labora-
tory: levels of triglycerides, high-density lipoproteins,
ratio of triglycerides and levels of non-high-density lipo-
protein cholesterol.
Food frequency and ESTEEM questionnaires
The ESTEEM food frequency questionnaire (FFQ) is
designed to assess habitual dietary intake over a speciﬁc
reference period in a pregnant population. It was
adapted from a validated FFQ speciﬁcally designed to
assess the dietary intake in a pregnant Mediterranean
population.18 We adapted the ESTEEM FFQ to capture
cultural foods commonly consumed in the study’s multi-
ethnic population. We obtained nutrients values from
the McCance and Widdowson’s Composition of foods
integrated data set19 and portion sizes from the Food
Standards Agency UK portion sizes.20 We will use the
methodology reported in the EPIC FFQ design21 to esti-
mate dietary intake by capturing frequency data of the
different nutrients and food groups.
We also developed a short food questionnaire of 12
items to assess the participants’ adherence to the dietary
intervention (The ESTEEM Q). The questionnaire was
developed based on a similar 14 items questionnaire
used in the PREDIMED trial to assess the adherence to
a Mediterranean-based dietary intervention and was
adopted to be used in a pregnant population.22 We will
collect both questionnaires at baseline and 36 weeks
from the control and the intervention groups.
The FFQ will be validated in the pilot phase against
multiple 24-hour food recalls using the multipass
method in a subsample of 65 randomised participants.
The agreement between daily intake of food groups,
energy, macronutrients and micronutrients estimated,
respectively, from the FFQ and from the 24-hour recalls
will be evaluated using intraclass correlation coefﬁcients.
To graphically check the agreement between the two
methods, we will use the analysis proposed by Bland and
Altman,23 using a plot of the differences between the
measurements against their means. Evidence of consist-
ent disagreement between the nutrients and food
intakes will be investigated using paired t-tests. We will
also identify the quintiles of intakes according to the
24-hour food recall data and the degree of gross mis-
classiﬁcation (the proportion classiﬁed into opposite
quintiles) and complete or adjacent agreement (the
proportion classiﬁed into the same or an adjacent quin-
tile) using the FFQ and 24-hour food recall data as add-
itional indices of validity.
The FFQ will be also used to validate the ESTEEM
questionnaire (ESTEEM Q) in the subsample of 65 par-
ticipants. We will use reported food intakes from the
FFQ to generate a response to each question on the
ESTEEM. The resulting FFQ-generated ESTEEM Q total
score will be compared against the actual ESTEEM Q
total score.22 The agreement between the two ESTEEM
Q total scores will be evaluated using intraclass correl-
ation coefﬁcients. To assess the convergent validity of
the ESTEEM Q total score, we will calculate the Pearson
product moment correlations between the actual
ESTEEM Q total score and nutrient intakes estimated
from the FFQ. We will use Kappa statistics to determine
the agreement between the scores for each of the 14
questions of the ESTEEM Q. We will also use the Bland–
Altman method to illustrate the agreement between the
scores of the FFQ and the ESTEEM Q total scores. We
will use a paired t-test to investigate any consistent dis-
agreement between the two scores.
Sample size
We expect the prevalence of the composite maternal
outcome of pre-eclampsia or gestational diabetes to be
24% and expect the ESTEEM dietary intervention to
reduce it by 30%. We will need 982 women to detect a
30% reduction in the primary outcome rate. After allow-
ing for a 20% dropout, we will need to randomise 1230
eligible women to ensure an 80% power at the 5% sig-
niﬁcance level. We expect the above sample size to have
an 80% power to detect a similar reduction in the com-
posite fetal outcome rate at the 5% signiﬁcance level,
while allowing for a 20% loss to follow-up and a similar
prevalence of 24%.
Statistical analysis
The effect of the treatment on the risk of composite
maternal and fetal outcomes will be estimated as an OR
with 95% CI, using a multivariable logistic regression. We
will adjust for the minimisation factors, as well as age,
history of previous gestational diabetes, family history of
hypertensive disorders (hypertension and/or pre-
eclampsia), family history of diabetes and history of still-
birth. These covariates have been selected based on prior
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evidence. Secondary outcomes will be analysed using a
multivariable logistic regression for binary outcomes and
a linear regression for continuous outcomes, with a nor-
malising transformation where necessary. Where a con-
tinuous outcome is also assessed at baseline, this will be
adjusted for as an additional covariate. Analyses will be
on an intention-to-treat basis. We do not anticipate any
missing primary outcome data, as the selected outcomes
should be recorded for all women and newborn infants.
However, should any primary outcome data be missing,
we will analyse participants with complete outcome data
only. This approach is unbiased if data are ‘Missing at
Random’. If the primary outcome is missing for more
than 5% of participants, then a sensitivity analysis will be
conducted to explore the ‘Missing at Random’ assump-
tion. Minimisation factors must also be non-missing for
participants to be randomised.
Subgroup and secondary analysis
The primary analysis of the treatment effect on the risk
of composite maternal and fetal outcomes will be
repeated separately within three subgroups: obese
women, women with raised triglycerides and women
with chronic hypertension. These subgroups will be ana-
lysed by statistically testing for an interaction term.
Subgroup-speciﬁc ORs will be reported with 95% CIs.
These analyses will be secondary and given less weight in
our conclusions than the primary analysis. Secondary to
the intention-to-treat analysis we will perform analyses of
the treatment effect which takes into account the partici-
pants’ compliance with the intervention using a
complier-averaged causal effect (CACE) analysis.
Internal pilot
We will dedicate the ﬁrst 3 months of the study for an
internal pilot to evaluate the rates of recruitment to the
trial and test the trial’s procedures. During the ﬁrst
3 months of study’s setup phase, we will obtain feedback
from service users on the design of the patient informa-
tion materials. During this period, we will also assess the
number of pregnant women screened for recruitment,
proportion of screened population who are eligible with
metabolic risk factors, the adherence to the protocol,
the ﬁdelity of the follow-up, the reasons for exclusion
from the trial, the proportion of eligible women partici-
pating in the trial and the reasons for which eligible
women declined participation in the trial.
If more than half of eligible women are not recruited
as anticipated by the end of the pilot phase, we will
survey the clinical staff early to identify any issues that
can be resolved to promote recruitment. Failure to
recruit more than 50% of the target population over the
ﬁrst 6 months of recruitment will lead to a review of trial
feasibility.
Data monitoring and confidential interim analysis
ESTEEM has a Trial Steering Committee (TSC) of four
independent members, including a representative from
APEC (Action on Pre-eclampsia), a charity dedicated to
the well-being of women diagnosed to have pre-
eclampsia and a service user with a history of pre-
eclampsia. There are also three independent members
on the Data Monitoring Committee (DMC). At the end
of the pilot phase, all data will be presented to the DMC
for conﬁdential review. Recommendations of the DMC
will be discussed with the TSC. There will be no gaps in
recruitment to continue the momentum built-up during
the pilot phase. All planned protocol amendments will
be discussed and approved by the TSC, Main REC and
the sponsor before taking action.
Data handling and confidentiality
The chief investigator has the overall responsibility to
ensure that the participants’ anonymity is protected and
maintained at all times in the study. All information col-
lected on the study participants will be kept conﬁdential
and managed in accordance with the Data Protection
Act (1998-UK), NHS Caldicott Guardian (Health
Service Circular: HSC 1999/012), The Research
Governance Framework for Health and Social Care and
the Research Ethics Committee Approval.
All data collected in the study will be entered onto a
dedicated password-protected electronic database using
a secure computer and internet connection. Paper case
report forms (CRF) will be used as a backup if required.
Data will be monitored centrally for consistency, viability,
quality and screened for out-of-range errors. We will
cross-check for conﬂicting data within and between the
CRF using computerised logic checking screens. In the
event of missing items or uncertainty in the records,
data will be referred back to the relevant centre for clari-
ﬁcation. Paper CRFs will be veriﬁed and processed on
site by the trial coordinators or other delegated team
members. Any data to be processed will be anonymised
prospectively. All personal information obtained for the
trial will be held securely and treated as strictly conﬁden-
tial. All staff members, at each hospital or the trials unit,
share the same duty of care to prevent unauthorised dis-
closure of personal information to any unauthorised
body. We will not publish any data that could lead to the
identiﬁcation of any study participants.
During the course of study, all records are the respon-
sibility of the chief investigator and will be kept in secure
conditions. On completion of the study, all records will
be kept securely by the sponsor for a further 20 years.
Quality assurance and auditing
The chief investigator will ensure that the trial is con-
ducted in compliance with the principles of the
Declaration of Helsinki (1996), and in accordance with
all applicable regulatory requirements including but not
limited to the Research Governance Framework, good
clinical practice (GCP), Trust and Research Ofﬁce pol-
icies and procedures and any subsequent amendments.
Non-compliance may be captured from a variety of dif-
ferent sources including monitoring visits, CRFs,
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communications and updates. The sponsor will maintain
a log of any non-compliance to ascertain if there are any
trends developing or escalating. The sponsor will assess
the non-compliances and resolve it within a ﬁxed time
frame.
The study sites will perform remote trial monitoring
as determined by the sponsor to verify the validity of
source data. A random sample of cases will be moni-
tored at source when site visits are performed. The
documents to be veriﬁed will be randomly selected. Any
major discrepancies found at a site visit would trigger a
more extensive audit of trial data at the site involved.
Adverse events
Any AEs, deﬁned as any unfavourable and unintended
sign (including an abnormal laboratory ﬁnding),
symptom or disease temporarily associated with study
activities, will be recorded in the participant’s individual
study ﬁle, the medical notes and the CRF with appropri-
ate follow-up by the research team.
Any serious adverse event (SAE), deﬁned as an unto-
ward occurrence of death, life-threatening condition,
hospitalisation or prolongation of existing hospitalisa-
tion, persistent or signiﬁcant disability or incapacity, con-
genital anomaly or birth defect or any condition judged
as medically signiﬁcant by the investigator, will be
reported to the study sponsor within 24 hours of learn-
ing of the event and to the main research ethics commit-
tee within 15 days.
ETHICS AND DISSEMINATION
NHS Research Ethics Committee approval was obtained
in all centres (UK IRAS integrated research application
system; reference 14/EE/1048). ESTEEM is registered
online with clinicaltrials.gov (NCT02218931).
The study collaborators will hold a meeting on com-
pleting the study to discuss and evaluate the main
results. The success of the study depends on the collab-
oration of a large number of stakeholders including
doctors, nurses, midwives, nutritionists and others. Thus,
the main credit for publishing the study’s results will be
dedicated to all collaborators equally. The trial manage-
ment committee will be responsible for publishing the
ESTEEM ﬁndings in high impact peer-reviewed journals.
Open access publications will be sought where possible
to maximise impact. All ESTEEM publications will follow
the ICMJE authorship guidelines. Oral and poster pre-
sentations will be sought in national and international
conferences of interest to the study topic to maximise
dissemination. Individual study centres will not be per-
mitted to publish partial data obtained from participants
in the ESTEEM study without discussion with the chief
investigator and/or the TSC.
DISCUSSION
Pregnancy offers an optimal period to motivate women
to adhere to healthier diet and lifestyle changes.24 The
role of behavioural and dietary-based interventions has
been increasingly evaluated to assess its beneﬁt in pre-
venting pregnancy complications. To date, no interven-
tion has been shown to be signiﬁcantly beneﬁcial.25
The ESTEEM study is speciﬁcally designed to test the
beneﬁcial role of a Mediterranean-based dietary inter-
vention in reducing metabolic risk factors in a high-risk
pregnant population.
The high intake of beneﬁcial food such as vegetables,
fruits, non-reﬁned grains, ﬁsh, extra virgin olive oil and
nuts and the reduced intake of high-fat food and red
meat characteristic of a Mediterranean diet have been
shown to improve lipid proﬁles, insulin sensitivity and
blood pressure.8 This protective effect is linked to the
increased intake of poly and mono-unsaturated fatty
acids readily available in a Mediterranean diet compared
to a modern Western diet.26 A low ratio of unsaturated
to saturated fatty acid in the diet has been linked to
adverse outcomes in pregnancy such as pre-eclampsia
and fetal growth restriction.27 However, available studies
are of poor quality and not sufﬁciently powered for spe-
ciﬁc pregnancy outcomes.6
The planned large study sample will provide ESTEEM
with adequate power to detect a reduction in primary
and secondary outcomes. The choice of the primary
composite outcomes was agreed with the TSC based on
input from multistakeholders in research on obesity in
pregnancy.28 Delivering the intervention via interactive
educational sessions coupled with dedicated grocery lists
and cooking recipes is aimed to improve the partici-
pants’ adherence to the intervention.29 Inducing and
maintaining dietary changes in pregnancy and beyond
could be challenging.30
Advocating a Mediterranean-based diet through educa-
tional intervention might not be sufﬁcient to introduce a
permanent change. Our strategy of providing cooking
recipes specially developed to adopt local food culture
and implement a Mediterranean cooking style could
help the participants to better understand and comply
with the intervention. The cost of acquiring nuts and
olive oil is relatively high in the UK which could present a
burden on the study participants. To improve adherence,
we opted to provide the participants with extra virgin
olive oil and mixed nuts throughout the study. This will
also ensure the continuous availability of these nutrients
throughout the lifetime of the study. The group sessions
are aimed to reinforce the knowledge and the education
on the beneﬁts of Mediterranean diet, promote healthy
eating habits, healthy shopping and sharing experiences
among participants and will provide opportunities to
explore obstacles and potential solutions.
Assessing adherence to the intervention is crucial to
accurately interpret dietary trials’ results. Using multiple
food diaries is generally considered to be the golden
standard tool for assessing dietary intake in dietary inter-
ventional trials.31 However using this tool in a pregnant
population can be quite cumbersome particularly for
participants who care for large families and are in full-
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time employment. While using an FFQ might offer a
better and more efﬁcient substitute, it still requires rela-
tively high literacy, a characteristic not always available in
our population of interest. It can also be less sensitive to
detect subtle changes in the dietary intake compared to
food diaries and 24 hour recalls.32 FFQs must also be
validated within the study population.31 This might be a
challenging task in ESTEEM due to the large variation
in ethnic groups, food cultures and dietary habits in our
population.
The use of a short screening tool such as the ESTEEM
Q will offer an easy and sensitive tool to assess the intake
of the nutrients of interest in the Mediterranean diet
such as extra virgin olive oil and nuts. Introducing this
short tool is far less complicated and can even be con-
ducted over the phone which will help to improve
returns. The limitation of using such tool is the limited
information collected on the whole diet and the narrow
focus on the Mediterranean nutrients’ intake. Women
will be recruited from multiple maternity units in the
UK, which will allow us to recruit a multiethnic popula-
tion with diverse food cultures. This will render
ESTEEM ﬁndings more generalisable and transferable
to clinical practice.
Some of the limitations in the design of the trial could
affect the interpretation of its ﬁndings. The nature of
the intervention makes it difﬁcult to blind the partici-
pants and the clinicians, which could introduce bias.
Furthermore, the control group will vary in the level of
care available to mothers at various maternity units. For
example, in some units, dietician support is provided for
women with a BMI ≥30 kg/m2 compared to >35 kg/m2
or none in other units. It is also possible that knowledge
of potential beneﬁts of the study may motivate some
women in the control group to follow the
Mediterranean lifestyle, which could bias the results.
Poor adherence to the intervention is clearly an
important factor that could bias the results of the trial.
Using self-reporting dietary tools such as the FFQ and
the ESTEEM Q will help us to estimate the adherence to
the dietary intervention. We will conduct a sensitivity
analysis of the treatment effect which takes account of
the compliance rate deﬁned by the attendance rate to
the intervention sessions throughout the study.
A better assessment of the dietary intake could be
achieved by using speciﬁc biomarkers such as hydroxy-
tyrosol for olive oil intake and α-linolenic acids for nuts
intake. Biomarkers offer an accurate and objective
assessment of the nutritional intake. Their use, however,
still has a number of limitations; it only offers a snapshot
view of the intake over a limited time period and can be
a relatively expensive and invasive tool.33 Recording the
return of empty packages can also provide a snapshot
view of the consumption of provided nutrients, however,
it is less speciﬁc and representative of the participant’s
individual intake.
There is increasing evidence on the possible beneﬁt of
Mediterranean diet on long-term childhood and maternal
outcomes. Observational data have shown a potential
reduction in childhood asthma and eczema following in
utero exposure to the diet.34 Furthermore, the effects of
nut exposure to pregnant mothers on subsequent nut
allergy in children needs evaluation. The effect of
Mediterranean diet on future risk of type 2 diabetes in
these women at high risk of metabolic factors is not known.
CONCLUSIONS
The ESTEEM trial will evaluate the beneﬁt of a
Mediterranean-based diet to reduce the risk of complica-
tions in pregnant women with high metabolic risk
factors.
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